Skip to main content
. Author manuscript; available in PMC: 2020 Dec 4.
Published in final edited form as: Oral Oncol. 2016 Aug 25;61:41–46. doi: 10.1016/j.oraloncology.2016.08.004

Fig. 2.

Fig. 2.

Quality of Life Outcomes. (A) Definitive TORS as a whole resulted in significantly better saliva-related QOL than definitive CRT at 1, 6, 12, and 24 months (p < 0.001, p = 0.025, p = 0.017, p = 0.011). However, among TORS patients, adjuvant therapy was associated with worse QOL in the saliva domain at 6, 12, and 24 months (p < 0.001, p < 0.001, p = 0.007). (B) Among TORS patients, adjuvant therapy was associated with worse QOL in the taste domain at 6 and 12 months (p = 0.067, p = 0.008).